Citius Pharma(US:CTXR)2026-02-13 13:00Revenue and Profitability - Revenue for the three months ended December 31, 2025, was $3,944,111, compared to no revenue in the same period in 2024[151] - Gross profit for the three months ended December 31, 2025, was $3,154,903, with a cost of revenues of $789,208[151] - Net product revenues for the three months ended December 31, 2025, were $3,944,111, with a gross profit margin of approximately 80%[154] Operating Performance - Operating loss for the three months ended December 31, 2025, was $9,019,208, an improvement from a loss of $10,039,614 in the same period in 2024[151] - Total operating expenses increased to $12,174,111 for the three months ended December 31, 2025, compared to $10,039,614 in 2024[151] - The company incurred a net loss of $9,393,889 for the three months ended December 31, 2025, an improvement from a net loss of $10,281,246 in the same period of 2024, reflecting a decrease of $887,357[166] Research and Development - Research and development expenses decreased to $1,599,719 for the three months ended December 31, 2025, from $2,127,038 in 2024[151] - Research and development costs for LYMPHIR decreased to $1,509,595 for the three months ended December 31, 2025, down from $1,727,540 in the same period of 2024, a decrease of 12.7%[159] - The amortization of in-process research and development was $573,438 for the three months ended December 31, 2025[151] - Amortization of in-process research and development for the three months ended December 31, 2025, was $573,438, commencing upon revenue generation from LYMPHIR[160] Cash and Financing - As of December 31, 2025, the company had an accumulated deficit of approximately $247 million and $7.7 million in cash, with a negative working capital of approximately $262,000[168] - The company received net proceeds of approximately $5.8 million from equity offerings during the three months ended December 31, 2025[169] - The company has outstanding milestone payments and purchase commitments totaling approximately $6.8 million to Eisai and $18.25 million to Dr. Reddy's as of December 31, 2025[172] Future Outlook - The company expects revenues to increase as LYMPHIR gains market acceptance, indicating a positive future outlook[155] Interest Income - The company recorded interest income of $45,097 for the three months ended December 31, 2025, compared to $22,608 in 2024[151] - Interest income for the three months ended December 31, 2025, was $45,097, compared to $22,608 in the same period of 2024, reflecting an increase of 99.5%[163] Milestones - The first commercial sale of LYMPHIR occurred in December 2025, marking a significant milestone for the company[148] - The company has limited revenues from the sale of LYMPHIR, which commenced in December 2025[135]